NCT05549804View on ClinicalTrials.gov

A Study of Intratumoral KL340399 in Patients with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

KL340399 Intratumoral

KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY